Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system.

This study developed a novel child-friendly drug delivery system for pediatric HIV treatment: a liquid, taste-masked, and solvent-free monoolein-based nanoparticles formulation containing indinavir (0.1%). Adherence to antiretroviral therapy by pediatric patients is difficult because of the lack of dosage forms adequate for children. Monoolein-based nanoparticles were developed. The particle size, zeta potential, pH, drug content, small angle X-ray scattering, stability, in vitro drug release profile, biocompatibility, toxicity, and taste-masking properties were evaluated. Monoolein-based formulations containing indinavir had nanosized particles with 155 ± 7 nm, unimodal particle size distribution, and polydispersity index of 0.16 ± 0.03. The zeta potential was negative (-31.3 ± 0.3 mV) and pH was neutral (7.78 ± 0.01). A 96% drug incorporation efficiency was achieved, and the indinavir concentration remained constant for 30 days. Polarized light microscopy revealed isotropic characteristics. Transmission electron microscopy images showed spherical shaped morphology. Small-angle X-ray scattering displayed a form factor broad peak. Indinavir had a sustained release from the nanoparticles. The system was nonirritant and was able to mask drug bitter taste. Monoolein-based nanoparticles represent a suitable therapeutic strategy for antiretroviral treatment with the potential to reduce the frequency of drug administration and promote pediatric adherence.

Citation

Mariana Domingues Bianchin, Germano Prebianca, Maira Frielink Immich, Mário Lettieri Teixeira, Mariana Colombo, Leticia Scherer Koester, Bibiana Verlindo de Araújo, Fernanda Poletto, Irene Clemes Külkamp-Guerreiro. Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system. Drug development and industrial pharmacy. 2021 Jan;47(1):83-91

Mesh Tags

Substances

PMID: 33289591

search → result